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Abstract
Background
In many low-income countries, care for patients with non-communicable diseases (NCDs)
and mental health conditions is provided by nurses. The benefits of nurse substitution and
supplementation in NCD care in high-income settings are well recognised, but evidence
from low- and middle-income countries is limited. Primary Care 101 (PC101) is a pro-
gramme designed to support and expand nurses’ role in NCD care, comprising educational
outreach to nurses and a clinical management tool with enhanced prescribing provisions.
We evaluated the effect of the programme on primary care nurses’ capacity to manage
NCDs.
Methods and Findings
In a cluster randomised controlled trial design, 38 public sector primary care clinics in the
Western Cape Province, South Africa, were randomised. Nurses in the intervention clinics
were trained to use the PC101 management tool during educational outreach sessions
delivered by health department trainers and were authorised to prescribe an expanded
range of drugs for several NCDs. Control clinics continued use of the Practical Approach to
Lung Health and HIV/AIDS in South Africa (PALSA PLUS) management tool and usual
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training. Patients attending these clinics with one or more of hypertension (3,227), diabetes
(1,842), chronic respiratory disease (1,157) or who screened positive for depression
(2,466), totalling 4,393 patients, were enrolled between 28 March 2011 and 10 November
2011. Primary outcomes were treatment intensification in the hypertension, diabetes, and
chronic respiratory disease cohorts, defined as the proportion of patients in whom treatment
was escalated during follow-up over 14 mo, and case detection in the depression cohort. Pri-
mary outcome data were analysed for 2,110 (97%) intervention and 2,170 (97%) control
group patients. Treatment intensification rates in intervention clinics were not superior to
those in the control clinics (hypertension: 44% in the intervention group versus 40% in the
control group, risk ratio [RR] 1.08 [95% CI 0.94 to 1.24; p = 0.252]; diabetes: 57% versus
50%, RR 1.10 [0.97 to 1.24; p = 0.126]; chronic respiratory disease: 14% versus 12%, RR
1.08 [0.75 to 1.55; p = 0.674]), nor was case detection of depression (18% versus 24%, RR
0.76 [0.53 to 1.10; p = 0.142]). No adverse effects of the nurses’ expanded scope of practice
were observed. Limitations of the study include dependence on self-reported diagnoses for
inclusion in the patient cohorts, limited data on uptake of PC101 by users, reliance on pro-
cess outcomes, and insufficient resources to measure important health outcomes, such as
HbA1c, at follow-up.
Conclusions
Educational outreach to primary care nurses to train them in the use of a management tool
involving an expanded role in managing NCDs was feasible and safe but was not associated
with treatment intensification or improved case detection for index diseases. This notwith-
standing, the intervention, with adjustments to improve its effectiveness, has been adopted
for implementation in primary care clinics throughout South Africa.
Trial Registration
The trial is registered with Current Controlled Trials (ISRCTN20283604)
Author Summary
Why Was This Study Done?
• Non-communicable diseases (NCDs) are the leading cause of deaths worldwide,
even in low- and middle-income countries (LMICs) that continue to battle to con-
trol communicable diseases like HIV and tuberculosis (TB).
• Effective and affordable treatments prevent complications from NCDs like heart
attacks and strokes, but access is limited by the variable availability and limited
capacity of primary care health workers to detect and effectively manage these con-
ditions. In many LMICs, non-physicians such as nurses provide primary care for
NCDs.
• Over the past 16 years, we have developed, evaluated, and refined integrated clinical
management tools and training programmes that employ problem-based
approaches to common symptoms like cough and priority health conditions
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including TB, HIV, asthma, and emphysema. We have shown them to be effective
in improving the quality and outcomes of care for communicable diseases.
• We have expanded this programme to include almost all NCDs and mental health.
This study evaluated the impact, both benefits and harms, of introducing the
expanded programme, called Primary Care 101 (PC101), in terms of the quality of
primary care for four common chronic diseases: hypertension, diabetes, chronic
respiratory disease, and depression.
What Did the Researchers Do and Find?
• We compared the care offered to patients with one of these four chronic diseases in
18 clinics in which primary care health workers were trained in the use of PC101
with that in 18 clinics where nurses continued to use the predecessor tool, which
focused on communicable diseases.
• The trial had a pragmatic design, meaning it was conducted under usual conditions
of health system operational constraints. Clinics in urban and rural areas serving
people living in socio-economically deprived areas of South Africa were selected.
• We enrolled 4,393 patients with one or more of the NCDs of interest and followed
them up for 14 mo after introduction of PC101 at the intervention clinics. The pri-
mary outcome of interest was intensification of treatment (or diagnosis, in the case
of depression) for the four NCDs, analysed separately.
• The results confirmed very high rates of multimorbidity (patients having more
than one condition at a time), under-diagnosis, under-treatment, and poor disease
control.
• Introducing PC101 did not result in intensification of treatment for the four NCDs,
but neither was there evidence of harm from the nurses’ expanded scope of
practice.
What Do These Findings Mean?
• The trial confirmed that multimorbidity and poor detection and control of NCDs
and depression are common in this setting. Interventions are necessary to limit the
impact of these conditions on people’s health and quality of life.
• PC101 offered a practical and acceptable tool to help expand the scope of practice
of non-physician clinicians to include NCD care, but we were not able to show
improvements in care, as we have previously done for communicable diseases.
• The study illustrates the limitations of trials designed to study the effects of complex
system interventions in real life, where even small changes across many endpoints,
as seen in our study, may be useful to decision-makers under pressure to respond
constructively to the rise of multimorbidity and NCDs.
• PC101 has been adopted for country-wide implementation in primary care clinics
in South Africa.
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Introduction
South Africa is facing a quadruple burden of disease: HIV and tuberculosis (TB); non-communi-
cable diseases (NCDs), including mental health conditions; injury and violence; and maternal,
neonatal, and childhood illnesses [1]. The past 15 years have seen concentrated efforts to
strengthen the capacity of the public health system to treat HIV and TB. These investments seem
at last to be paying off, with a rise in life expectancy, a decline in mortality [2], and fewer new HIV
infections [3]. Yet the burden of NCDs and mental health remains unchecked; cardiovascular dis-
ease is now the second leading cause of death in South Africans after communicable diseases [4,5].
In South Africa, responsibility for the detection and treatment of NCDs lies at the primary
care level, with nurses seeing nine out of ten patients, most of whom have more than one pre-
senting condition [6]. However, the quality of NCD care is generally poor, characterised by
under-diagnosis, under-treatment, and poor clinical control [1,7,8]. We have previously suc-
cessfully piloted and trialled task-sharing interventions for communicable diseases, increasing
the capacity of nurses to take on assessment and prescribing roles for HIV and TB previously
restricted to doctors [9–15]. This programme has been scaled up throughout South Africa as
part of the national government’s accelerated response to HIV and TB launched in 2010 [16].
A similar programme has been developed for use in other countries including Malawi,
Botswana, Brazil, and Mexico [17]. We have since expanded this programme, now called Pri-
mary Care 101 (PC101), to include NCDs and mental health, hoping to leverage the health sys-
tem reforms that accompanied the scale-up of antiretroviral therapy (ART) to improve the
quality of primary care for other priority conditions.
These integrated programmes of care seek to overcome the limitations of vertical services
that tend to neglect multimorbidity [18–23], and to expand the roles of nurses, increasing the
number and distribution of health workers providing treatment for common NCD conditions.
While the benefits of nurse substitution and supplementation for a limited number of
NCDs in high-income settings are well recognised [24], evidence from low- and middle-
income countries (LMICs) is sparse and limited to a few pilot studies [25–28]. Fewer studies
still have sought to improve care across several NCDs simultaneously. Meta-analyses of com-
plex interventions in health systems confirm only small effect sizes (ranging from 0.4% to
6.3%) for carer behaviour (improved care), but given the size of the populations affected, these
effect sizes are considered important, provided the interventions are introduced without harm.
We report here the findings of the PC101 Trial, a pragmatic cluster randomised study evaluat-
ing the effectiveness of the PC101 intervention, which combines provision of an integrated
management tool with educational outreach to nurses. The primary outcomes of interest were
intensification of treatment for hypertension, diabetes, and chronic respiratory disease and
case detection of depression in overlapping cohorts of patients with these conditions.
Methods
Ethical approval for the trial was obtained from the University of Cape Town Human Research
Ethics Committee (reference number 119/2010) and the Western Cape Department of Health.
Study Design
This was a pragmatic, parallel-group cluster randomised controlled trial performed in the
Eden and Overberg districts of the Western Cape Province. Clusters were public sector pri-
mary healthcare clinics randomised within six sub-district strata. Outcome measures in each
of four cohorts were assessed in individual patients. Patient cohorts overlapped; patients with
more than one condition of interest were included in each applicable cohort, and cohorts were
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powered and analysed separately. This study design, with multiple cohorts, each with its own
primary outcome evaluated simultaneously, aimed to reflect the realities in primary care clinics
that nurses are required to diagnose and manage a wide range of conditions, that NCDs are
associated with multimorbidity, and that a focus on one condition may compromise the man-
agement of others [29]. The Western Cape Department of Health provided consent for the
inclusion and randomisation of clinics, before randomisation was performed. Patients provided
written consent for data collection after randomisation of clinics and prior to data collection.
Participants
Clinics. The study was conducted in the predominantly rural districts of Eden and Over-
berg, where public sector clinics serve a population of around 800,000, mainly people with
lower socio-economic status. Busy town clinics had fulltime doctors, but most clinics were
nurse led, with doctors in attendance on a sessional basis (Table A in S1 Appendix).
Eligible clinics provided services, including for NCDs, at least five days a week and reported
more than 10,000 attendances per year, so were likely able to contribute sufficient numbers of
patients to the study. Of 124 clinics in the Eden district, 33 clinics in five sub-districts met
these criteria. We supplemented this sample with five clinics from a sub-district in an adjacent
district (Overberg), to increase the number of clinics available for randomisation and
strengthen the study’s power.
The health districts in the study are representative of health services offered to more than
80% of the population of South Africa, comprising clinics both from medium-sized towns and
rural areas [6].
Patients. The study population comprised patients with one or more of the following:
hypertension, diabetes, chronic respiratory disease, or depression. Initial eligibility criteria
were being 18 y or older, likely to reside in the area for the next year, and capable of actively
engaging in an interviewer-administered questionnaire at the time of recruitment. Inclusion
criteria for the four cohorts were as follows (Table 1): for the hypertension and diabetes
cohorts, if patients reported being on medication for hypertension or diabetes, respectively;
for the respiratory disease cohort, if they reported receiving medication for chronic airway dis-
ease (asthma or chronic obstructive pulmonary disease [COPD]) or reported a cough and/or
difficult breathing for 2 wk or more prior to enrolment and were not on treatment for TB [30];
for the depression cohort, if they scored ten or more on the 10-item Center for Epidemiologic
Studies Depression Scale (CESD-10) [31,32]. We selected this instrument because the 20-item
version has been validated in a similar setting in South Africa [33], and the 10-item version in
primary care populations elsewhere [34–36]. The shorter version was necessary to limit the
length of the screening process for all four conditions. Patients were eligible even if at the time
of enrolment they had no record of current treatment for their condition.
In keeping with the study’s pragmatic design, enrolment was not restricted to patients with
uncontrolled disease or to patients considered to be adherent to current treatment [40].
Although encouraging adherence was included in the management tool, it was not monitored.
Randomisation. Clinics within each of six health sub-district strata were randomised to
avoid potential confounding resulting from geographically determined differences in manage-
ment of clinical services. Two strata contained equal numbers of clinics, meaning that rando-
misation could be done in a 1:1 ratio. The four strata containing odd numbers of clinics were
randomly allocated to have either one more or one fewer intervention clinic than control clin-
ics, to achieve an equal number of clinics in each group (19 per group, 38 in total).
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Randomisation was completed by the trial statistician using nQuery Advisor after recruit-
ment of clinics, independently of the managers giving permission for the clinics to be included
in the trial, and prior to patient recruitment and implementation of the intervention.
Setting and Programme
Usual care for non-communicable and communicable diseases (control group). South
African primary care clinics provide free services for communicable disease and NCDs.
Patients are seen by a clinician, usually a nurse, and stable patients with NCDs are seen at
intervals of 3–6 mo, but are required to collect medications each month either from the clinic
or from an off-site medication pick-up point. The clinical load borne by nurses is great; in
2008 the median number of patients per nurse seen each working day in the clinics studied
Table 1. Eligibility criteria, primary outcome definitions, and required sample size estimates for each cohort.
Cohort Eligibility Criteria Primary
Outcome
Primary Outcome Definition Required Sample Size Parameters1
Cluster
Size
Intervention
Proportion
Control
Proportion
ICC
Hypertension Self-reported
antihypertensive medication2
Treatment
intensification
(1) an increase in the number of
antihypertensive medication classes
and/or (2) an increase in dose of at
least one antihypertensive and/or (3)
a switch to an antihypertensive in
another medication class and/or (4) a
switch to an antihypertensive in the
same medication class provided that
the new dose is equivalent to a
higher dose of the previous
antihypertensive and/or (5) addition
of aspirin and/or (6) the addition or
increase in dose of a statin.
57 0.36 0.25 0.04
[37]3
Diabetes Self-reported hypoglycaemic
medication4
Treatment
intensification
(1) the addition or increase in dose of
metformin and/or (2) the addition or
increase in dose of a sulphonylurea
and/or (3) the addition or increase in
dose of insulin and/or (4) the addition
or increase in dose of an ACE
inhibitor and/or (5) addition of aspirin
and/or (6) the addition or increase in
dose of a statin.
57 0.36 0.25 [38]3 0.04
[37]3
Chronic
respiratory
disease
Self-reported respiratory
medication OR cough and/or
difficult breathing >2 wk (and
not on TB treatment)5
Treatment
intensification
(1) the addition or increase in dose of
an inhaled corticosteroid and/or (2)
addition of a beta-agonist and/or (3)
addition of ipratropium bromide and/
or (4) addition of theophylline.
36 0.30 0.15 0.02
[15]3
Depression CESD-10 10 Case detection (1) addition of antidepressant
medication and/or (2) receipt of
counselling by a mental health
practitioner and/or (3) referral to
mental health services.
60 0.10 0.04 0.04
[39]3
1All calculations are for two-sided tests and are powered at 90%. Sample sizes have been inflated by 20% to allow for loss to follow-up at 14 mo.
2Patients included in this cohort responded yes to the following question: “Are you taking medicine for high blood pressure (hypertension)?”
3These parameters were derived from earlier publications.
4Patients included in this cohort responded yes to the following question: “Are you taking medicine for diabetes (“sugar”)?”
5Patients included in this cohort responded yes to either of the following questions: “Are you taking medicine for asthma or chronic bronchitis or
emphysema?” or “Do you have cough or difficult breathing which has lasted for more than two weeks?”
CESD-10, 10-item Center for Epidemiologic Studies Depression Scale; ICC, intraclass correlation coefficient.
doi:10.1371/journal.pmed.1002178.t001
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was 25. Although all clinics were attended by doctors, in more than half this was on a part-
time basis rather than daily (Table A in S1 Appendix). National regulations require that pre-
scriptions be renewed and co-signed by a doctor at least every 6 mo, a process that is time-con-
suming, reducing opportunities for the doctor to review complex cases and mentor nurses.
The selection of medications and level of prescribing provisions (nurse versus doctor) are gov-
erned by the South African national essential medicines list and standard treatment guidelines
[41], which are revised by the National Department of Health every 5 y. Nurse prescribing pro-
visions differ by province and, prior to the trial, were limited in the Western Cape to first-line
medications such as thiazide diuretics for hypertension, metformin for diabetes, and low-dose
inhaled corticosteroids for asthma. Prescription of antidepressants, which is governed by regu-
latory conditions for high schedule medications, is restricted to doctors.
Guidelines and policies for communicable diseases change more frequently than those for
NCDs. Guidelines for both tend to be lengthy and text-heavy, at times containing confusing
differences in recommendations for the same condition. To address this issue, we developed
and implemented the Practical Approach to Lung Health and HIV/AIDS in South Africa
(PALSA PLUS), a management tool that integrates guidelines and configures them concisely
and simply in an algorithmic format that more closely aligns with presentations in primary
care (symptoms and follow-up for chronic conditions) and ensures harmonisation of disease-
specific guidelines. It also clarifies prescriber levels (nurse versus doctor) [13,17,42]. It was
implemented in two provinces in 2006 (Western Cape and Free State), and in all nine prov-
inces of South Africa between 2010 and 2011. Since 2007 it has included provision for nurse
initiation and re-prescription of ART. This inclusion was based on the results of a large prag-
matic randomised controlled trial performed in the Free State Province that showed that
nurses were as effective as doctors in providing ART care [9,11,12], and on a second trial in
the Western Cape and Gauteng Provinces that evaluated nurse re-prescription of ART [43].
This development was prompted by the urgent need to expand ART services in South Africa.
Use of the latest (2011/2012) version of PALSA PLUS was the standard of care in control clin-
ics during the PC101 Trial. Prior to the development of PC101, nurses were required to man-
age NCDs, but they received relatively little training and support, resources for NCD
management were not user-friendly, and initiation or intensification of NCD medications was
largely dependent on the availability of doctors. The introduction of PALSA PLUS was the
first attempt to change this pattern; providing more user-friendly management tools that
expanded nurses’ scope of practice and prescribing with increasing “diagonal” integration.
A second key component of the PALSA PLUS programme is training clinicians to use the
management tool. This component employs an educational outreach model [44] in which facil-
ity trainers, typically nurse middle managers, are trained and equipped to deliver repeated short
(1.5 h), onsite, interactive training sessions using carefully constructed case scenarios [42]. Cli-
nicians are trained to use the tool as a care pathway in case management and to use it during
each consultation. Follow-up “refresher” training accompanied distribution of the revised man-
agement tool each year. By 2011, around 70% of all nurses working in the trial districts had
received initial training in PALSA PLUS, and training continued as usual in the control clinics.
An unanticipated change in usual care in the health districts under study was a shift in
focus from communicable disease care to NCD care. Midway through the trial, the district
health department launched a 3-mo campaign called Chronic Disease Season in all clinics to
improve NCD recognition and care. Chronic Disease Season focused on hypertension and dia-
betes and involved both community and clinic health workers. The community-level interven-
tions included several “health screening days” in which free blood pressure and finger-prick
glucose measurements were offered at venues such as shopping centres and town halls. People
with high values were referred to local clinics. In addition, around 10% of community health
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workers (33 in total) were equipped to provide basic education on lifestyle measures including
diet and physical activity.
Intervention rationale. The PC101 intervention was a further development of the PALSA
PLUS programme, aimed to include all common symptoms and conditions, including NCDs,
among adults attending primary care services. This expanded scope was strongly motivated by
input from primary care nurses and managers, who reported that coverage for NCDs in
PALSA PLUS, particularly hypertension and diabetes, would greatly improve its usefulness.
The implementation of PC101 aimed to use the same educational outreach approach as used
for PALSA PLUS. This educational approach was shown in three pragmatic trials to be effec-
tive for the management of communicable diseases. Beneficial effects included reproducible
and substantial improvements in TB case detection [9,13,15]; increases in appropriate pre-
scribing, including inhaled corticosteroids for asthma [15], co-trimoxazole prophylaxis for
HIV [13], and appropriate switching to second-line ART [9]; and appropriate referral of severe
[15] and complex cases [9]. Changes in healthcare utilisation included fewer and shorter hos-
pital admissions and a higher number of primary care visits [9,13,15]. The impact on health
worker morale was also documented in parallel qualitative evaluations, with nurses reporting a
sense of empowerment and emphasising the value of combining simplified diagnostic and
treatment algorithms, onsite training, and expansions in prescribing provisions [12,42]. No
harmful effects of the intervention were noted.
Intervention materials. The main intervention material was a 101-page evidence- and pol-
icy-informed algorithmic management tool. Based on PALSA PLUS, it was developed over a
period of 5 y (2006–2011) with input from specialist clinicians, primary care doctors and nurses,
allied health professionals, managers, and representatives of patient advocacy groups. The selec-
tion of content was based on the results of a cross-sectional survey in 18,000 consultations in
primary care clinics across four provinces in South Africa of the most common reasons for
attendance. The first half of PC101 covers 40 of the most common symptoms in adults attending
primary care and prompts screening for the 20 chronic conditions included in the second half of
the tool [6]. The selection of chronic conditions took a health services approach, including those
that required regular planned follow-up in primary care. Included were communicable diseases
(HIV, TB, sexually transmitted infections), NCDs (diabetes, hypertension, asthma, COPD, epi-
lepsy), mental health conditions (depression, substance abuse, schizophrenia, dementia), and
women’s health (contraception, antenatal care). Content was extracted from existing disease and
policy guidelines and structured in a simple summative form: one page for “diagnosis” and one
to two pages for follow-up “routine care” (organised under the headings of “assess”, “advise”,
and “treat”) for each condition. Promotion of integrated care was a key objective. Extensive use
was made of algorithms and checklists to optimise presentation of content, and provide action-
able support that is readily applied during consultations. Content for diverse conditions was
organised in a standard format; symptom pages prompted screening for multiple chronic condi-
tions, and pages on the routine care of chronic conditions included screening for common
comorbidities. In addition, care was taken to ensure that recommendations that were applicable
to multiple pages of the tool, such as blood pressure thresholds for diagnosis, treatment, and life-
style advice, were harmonised and consistently reflected. The management tool was provided as
a ring-bound, high-quality, full-colour illustrated booklet to every clinician (nurse and doctor)
responsible for primary care in the 19 intervention clinics. The tool is updated annually to reflect
changes in evidence, policy, and feedback from clinicians and managers. For examples of
updated content, see http://knowledgetranslation.co.za/programmes/pack-adult/.
The case scenarios used for training built on a set that had been extensively used during
PALSA PLUS implementation. An illustration of a typical waiting room scene provided a cast
of characters, each of whom was fleshed out in a case scenario (Table B in S1 Appendix). The
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cases were carefully constructed to build familiarity with use of the management tool, grow
knowledge specifically related to NCDs and depression, and scaffold development of knowl-
edge and skills [45], moving from straightforward clinical presentations toward greater com-
plexity and multimorbidity. The cases formed the basis for the educational training sessions
(Table B in S1 Appendix). A desk-blotter with a calendar illustrating key messages for priority
conditions was provided to all staff in intervention clinics, to facilitate booking of follow-up
appointments and to remind clinicians of essential elements of care.
Training. Six health department nurse trainers with experience in primary care and with
responsibility for existing training initiatives within the study districts—including Integrated
Management of Childhood Illness, PALSA PLUS, and ad hoc training in the TB programme—
and with a support role for nurses were employed as facility trainers for the study. They were ini-
tially trained in PC101 during a 5-d live-in training course in May 2011. This course was led by
an experienced adult education practitioner with a background in nursing (G. F.) and the family
doctor who had led the expansion of the management tool (R. C.). The programme adopted a
strong experiential focus, and gave as much attention to equipping the nurse trainers to be edu-
cators as it did to the expanded content of the management tool. It included multiple practice
sessions during which the nurse trainers facilitated case-scenario-based training sessions with
their peers, followed by critical feedback. It included exercises to help each trainer understand
their own learning style [46] and to learn reflective practice. Facility trainers delivered eight
short (1.5 h), on-site, interactive educational outreach sessions using the PC101 management
tool and case scenarios to all clinical staff at intervention clinics over several weeks. In all, 155
face-to-face educational outreach sessions were held at the 19 intervention clinics, eight sessions
in each clinic. Owing to clinical demands and absences due to night duties or annual sick or
study leave, not all staff were able to attend every session. In total, 81 nurses (who each partici-
pated in a median of six sessions), five pharmacists, and four doctors were trained. The trainers
received no payment from the research team. In addition to on-site training, nurse trainers pro-
vided support to staff through regular visits during which they would discuss difficult cases,
review folders of patients whose care nurses had changed using PC101, or jointly see patients.
The nurse trainers themselves were supported through quarterly 1-d workshops, facilitated
by G. F. These workshops included opportunities to report back on training at the clinic, trou-
bleshoot difficulties in scheduling or completing educational outreach sessions, resolve queries
related to the clinical content of the management tool, and practise facilitation skills. They also
aimed to continue the community of practice that had been established during the initial live-
in training.
Expanded prescribing provisions. Professional nurses who successfully completed the
educational outreach were authorised by the district manager to prescribe an additional seven
medications for NCDs previously restricted to doctors: enalapril and amlodipine for hyperten-
sion, glibenclamide and gliclazide for diabetes, simvastatin for increased cardiovascular risk,
inhaled budesonide for asthma, and short courses of oral prednisone for exacerbations of
COPD (Table C in S1 Appendix). These expansions were clearly reflected in the management
tool, which colour-coded all medications to reflect whether they could be prescribed by a doc-
tor or a nurse or only by a doctor, and were also communicated to clinic managers by way of a
circular from the district managers. The expanded prescribing provisions initially resulted in
some tensions between nurses, doctors, and pharmacists. These were resolved through a facili-
tated group session and informal communication within clinics, sometimes involving the
nurse trainer. This intervention was the only modification to the training during the trial.
Intervention monitoring. The integrity of the intervention was assessed in several ways.
Nurse trainers were observed during the initial live-in course and at quarterly follow-up work-
shops. Two nurse trainers were interviewed, and, in December 2011, focus group discussions
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were held with nurses in four intervention clinics. Nurses representing both rural and small
town locations were enthusiastic about the management tool and recognised that it was a new
way of strengthening care for NCDs. In particular they appreciated the format and the stan-
dardised framework for providing routine care, and the familiar features shared with PALSA
PLUS. Consistent with our previous experience with PALSA PLUS, some variation in uptake
of the management tool by nurses was reported. There was a tendency for nurses who formerly
used PALSA PLUS to adopt PC101 and use it regularly, whereas nurses who had not used
PALSA PLUS were less likely to begin to use the new management tool routinely [11,12].
Uptake by the trainers was considered excellent, and trainers completed planned sessions in all
intervention clinics, some repeating sessions to ensure coverage of most staff.
Data Collection
Fieldworkers recruited from local communities were trained to collect the trial data. They
invited patients seated in the waiting rooms to be considered for the study and screened them
using a structured questionnaire. Patients who met the eligibility criteria (Table 1) and pro-
vided informed consent were enrolled in the trial and completed the baseline questionnaire in
Afrikaans, isiXhosa, or English, administered by the fieldworker using a handheld electronic
device. Anthropometry (weight, height, waist circumference) and blood pressure were
recorded [47]. Patients were asked to attend a follow-up interview 14 mo after their baseline
interview. The lengthy period between interviews was intended to allow adequate opportunity
for health workers to intervene in the care of trial patients, given that chronic disease patients
are seldom reviewed at clinics more often than every 3–6 mo.
The questionnaire included questions on medical history, smoking status, mental health,
health-related quality of life, and socio-economic status. The severity of respiratory symptoms
among patients in the respiratory cohort was assessed using the symptom and activity domains
of the St George’s Respiratory Questionnaire [48]. Patients who chose to complete the inter-
view in isiXhosa were excluded from this section of the interview as there is no tested isiXhosa
translation of this instrument. The presence of symptoms of depression was assessed with the
CESD-10, administered to all patients enrolled in the study [32].
Depression treatment was defined as having received counselling, having been referred to
psychiatric services, or being on an antidepressant at a therapeutic dose. Low-dose amitripty-
line and imipramine are widely prescribed in South Africa for pain management or insomnia.
We therefore defined antidepressant use at a therapeutic dose as prescription of amitriptyline
or imipramine 50 mg daily and/or any other antidepressant. Counselling was defined as
“talking with someone in a way that helps to find solutions to problems, or receive emotional
support, and not just receiving advice on how to take medication.”
Fieldworkers extracted and photocopied patients’ prescription charts from their folders,
clinic stores, and pharmacies for the year preceding the baseline interview. The medically qual-
ified trial manager (N. F.) analysed all prescription charts and recorded prescriptions of
chronic medication for each patient at the time of their interview. A data capturer entered the
prescription data (medication, dose, and frequency) into a database, and the total daily dose
for each medication was calculated. Prescription, interview, and laboratory data were imported
and stored in a SQL server database, and a single longitudinal record constructed for every
patient by the study database scientist (V. T.).
Reminder letters and cell phone text messages were sent to patients in the month preceding
their scheduled follow-up interview. Patients who failed to attend this appointment were
traced by phone or home visit. Patients received a gift voucher for a local grocery store with a
value of ZAR100 (US$12.25) on completion of the follow-up interview, to compensate for
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travel costs and time. The follow-up questionnaire was similar to the baseline questionnaire,
and fieldworkers repeated the anthropometry and blood pressure measurements. At follow-
up, prescription data for the period since baseline were extracted, photocopied, analysed, and
documented in the same way as at baseline.
Quality control measures included supervision of fieldworkers, electronic alert messages
for fieldworkers if unusually high or low values were entered into the electronic questionnaire,
monitoring of the data to identify unusual values or trends, and double entry of prescription
data. At follow-up, prescription data were queried if they were missing, if the date of the pre-
scription fell outside of a 1-mo window period based on the scheduled re-interview date, or if
cohort-specific medications were excluded.
Blinding of the intervention was not possible at the clinic level due to the nature of the
intervention.
Outcome Measures
The primary outcome for hypertension, diabetes, and chronic respiratory disease was treat-
ment intensification, reflected by an increase in dose or number of medications or change in
medication class. This outcome was chosen after considering research identifying clinician
inertia as a key reason for failure to control these conditions [49,50]; treatment intensification
is associated with improved control [51–53]; was likely appropriate for the study population,
where under-treatment was highly prevalent [1,7,8]; fitted well with the focus of the interven-
tion on the clinical practices of nurses and the expansion of their prescribing with training;
and could be applied across three of the four chronic conditions of interest. Definitions of
treatment intensification by cohort are summarised in Table 1. For the depression cohort, case
detection was selected as the primary outcome because depression is recognised to be under-
diagnosed and under-treated in primary care [54].
Secondary outcome measures were as follows: disaggregation of primary outcomes by type
of medication; cardiovascular disease risk and risk factors such as blood pressure, body mass
index (BMI), and smoking status; health-related quality of life measured using the EuroQol-
5D [55] and the World Health Organization Disability Assessment Schedule 2.0 (WHODAS
2.0) [56]; mortality; and healthcare utilisation. These last four outcomes were designed to
detect evidence of harm resulting from shifting clinical responsibility from doctors to nurses,
an often overlooked consideration in evaluations of task-shifting [57].
Sample Size and Statistical Power
The study was powered to detect clinically important differences in primary outcomes within
each cohort, accounting for the cluster randomisation design. With 38 clinics available for ran-
domisation, we calculated the number of patients needed per clinic for each cohort to detect
differences in primary outcomes of between 10% and 15%, with 90% power, 5% significance,
and intraclass correlations of outcome based on previous studies, and assuming 20% loss to
follow-up (Table 1). Baseline rates of treatment intensification were not available in South
Africa, and so we used rates from studies completed in high-income settings [50,58].
HbA1c was measured as part of the pre-planned blood sampling strategy in a subgroup of
clinics because resource limitations meant that we could not measure it in all diabetic patients
in all 38 clinics. We estimated that HbA1c tests were needed from 30 diabetic patients in 10
clinics in each group (i.e., 600 diabetic patients from 20 clinics in total) in order to a show a dif-
ference of 0.5% (HbA1c of 8.8% in the control group versus HbA1c of 8.3% in the intervention
group, assuming a standard deviation of 3.4%).
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Analysis
We compared baseline clinic and patient characteristics between treatment groups. All clinics
and patients were analysed in the treatment group to which they were randomly assigned. Pri-
mary and secondary outcomes were analysed at the patient level, separately within each cohort.
No adjustment was made for the multiple disease-specific primary outcomes. The cluster ran-
domisation design was accounted for using robust cluster variance-covariance estimates.
Intervention effects were estimated using binomial regression models with treatment as the
main effect, adjusted for stratification, and are reported with 95% confidence intervals. Sec-
ondary analyses were further adjusted for potentially confounding baseline characteristics
such as treatment status and disease control at baseline, smoking status, age, sex, and co-mor-
bidity with one of the study diseases.
We carried out pre-specified subgroup analyses of the primary outcomes stratified by base-
line level of disease control using binomial regression models including baseline disease con-
trol as a covariate. Baseline disease control of hypertension was defined as blood
pressure < 140/90 (or, in patients with diabetes or a history of cardiovascular disease, <130/
80), and for diabetes, as HbA1c < 7%. For depression, since the outcome was detection, “con-
trol” was defined as any patient receiving treatment for depression as follows: being on antide-
pressant medication at therapeutic dosage or having received counselling in the past year or
having been referred to psychiatric services in the last year. No definition of disease control
was applied to patients with chronic respiratory disease. Heterogeneity of the intervention
effect was assessed by looking at the interaction between treatment and baseline disease con-
trol. In addition, we pre-specified secondary analyses of the primary outcomes disaggregated
by component. For the primary outcomes, missing data were considered not to have occurred.
We used linear regression to compare changes between baseline and follow-up in blood
pressure, waist circumference, weight, BMI, HbA1c, and health status measures between the
treatment groups, adjusted for stratification. Similarly, we used ordinal logistic regression to
compare readiness to quit smoking, and Poisson regression to compare rates of healthcare uti-
lisation between the treatment groups. Stata version 13.0 statistical software was used for all
analyses.
Results
Fig 1 shows the trial profile. All 38 randomised clinics completed the trial. In all, 4,904 patients
were screened, of whom 4,393 patients met the eligibility criteria and were enrolled in the trial.
Recruitment targets were exceeded for all cohorts except for diabetes, where recruitment fell
short of targets. Enrolment of patients took place between 28 March 2011 and 10 November
2011 and was completed in intervention clinics before educational outreach sessions to nurses
began. Follow-up data collection began on 21 May 2012 and ended on 13 December 2012.
In all, 1,927 patients in the intervention group were interviewed at follow-up (1,927/2,166;
89%), and 2,050 in the control group (2,050/2,227; 92%). Reasons for not being re-interviewed
were similar between groups: death (63 in the intervention group versus 54 in the control
group); relocation (42 in the intervention group versus 26 in the control group); too ill to be
re-interviewed (two in the intervention group versus zero in the control group); and could not
be traced (132 in the intervention group versus 97 in the control group). Prescription charts
could be traced, and thus the primary outcome ascertained, for 206 patients who were not re-
interviewed in the intervention group, and 151 in the control group, accounting for the very
high rates of patients contributing data to the primary endpoint analysis (Fig 1).
Baseline patient characteristics are presented in Table 2 and detailed in a separate publica-
tion [47]. Baseline clinic characteristics are provided in Table A in S1 Appendix. Intervention
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Fig 1. Trial profile. NCD, non-communicable disease.
doi:10.1371/journal.pmed.1002178.g001
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Table 2. Characteristics of patients allocated to an educational outreach programme (intervention
group) or no new training (control group).
Characteristic Intervention Control
Patients recruited 2,166 (49) 2,227 (51)
Women 1,573 (73) 1,621 (73)
Age (years): median (IQR) 51 (42–61) 53 (44–62)
Language selected for the interview
• Afrikaans 1,794 (83) 1,885 (85)
• isiXhosa 145 (7) 192 (9)
• English 227 (11) 150 (7)
Highest education level achieved
• Tertiary education 40 (2) 35 (2)
• Secondary school education 923 (43) 930 (42)
• Primary school education 818 (38) 940 (42)
• No schooling 146 (7) 145 (7)
• Not obtained 239 (11) 177 (8)
Employed or self-employed 557 (26) 531 (24)
Receiving a social government grant 1,205 (56) 1,323 (59)
Housing density1: median (IQR) 2 (1–2), n = 1,426 2 (1–2), n = 1,505
Multimorbidity
• Hypertension only 304 (14) 326 (15)
• Diabetes only 72 (3) 76 (3)
• Chronic respiratory disease only 61 (3) 74 (3)
• Depression only 269 (12) 220 (10)
• Two conditions 911 (42) 949 (43)
• Three or four conditions 549 (25) 582 (26)
Past medical history
• Known cardiovascular disease (heart attack, angina,
stroke)
605 (28) 505 (23)
• Previous tuberculosis 237 (11) 255 (12)
• History of hypertension 1,590 (73) 1,718 (77)
• History of diabetes 854 (39) 998 (45)
• History of depression 525 (24) 558 (25)
Smoking history
• Current 652 (30) 731 (33)
• Past 464 (21) 550 (25)
• Never 1,022 (47) 921 (41)
• Not obtained 28 (1) 25 (1)
Pack-year history for current and ex-smokers: median (IQR) 7 (3–15), n = 869 7 (3–13), n = 1,064
Hospitalisation in 3-mo period preceding interview 134 (6) 136 (6)
BP 140/90 mm Hg2 1,055 (49) 1,216 (55)
BP 180/110 mm Hg2 166 (8) 193 (8)
Weight (kg): mean (SD) 77 (20), n = 2,111 77 (19), n = 2,179
BMI (kg/m2): mean (SD) 30 (8), n = 2,060 30 (8), n = 2,104
Obese (BMI 30 kg/m2) 972 (45) 1,008 (45)
Waist circumference (cm): mean (SD) 98 (16), n = 2,140 98 (16), n = 2,205
Waist circumference more than ideal2 1,316 (61) 1,381 (62)
10-y non-laboratory-based cardiovascular disease death risk
(percent)3: mean (SD)
22 (20), n = 1,335 26 (21), n = 1,327
(Continued )
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and control clinics had similar numbers of nurses and doctors. Control clinics tended to be
larger and, by chance, had more psychiatric services and on-site pharmacy facilities.
Baseline patient characteristics were generally well balanced between arms. Seventy-three
percent of patients were women, and the median age was 52 y. There were high levels of unem-
ployment and receipt of social welfare grants. Multimorbidity was common: 42% of patients
had two conditions, and 26% more than two. The percentage of patients with a single condi-
tion of interest was as follows: hypertension, 20% (630 of 3,227); depression, 20% (489 of
2,466); diabetes, 8% (148 of 1,842); and chronic respiratory disease, 12% (135 of 1,157). A
quarter of patients reported established cardiovascular disease. Eleven percent reported previ-
ous TB, and 2% reported being on ART. There were signs of under-treatment and under-diag-
nosis, with 18% of hypertensive patients reporting no or only one current antihypertensive
medication, only 51% of diabetic patients receiving statins, only 50% of those with chronic
respiratory disease or symptoms receiving any respiratory medication, and only 25% of those
who screened positive for depression reporting some form of relevant treatment for the
condition.
There was poor control of hypertension and diabetes despite treatment: blood pressure was
140/90 mm Hg in 59% of hypertensive patients, and HbA1c was7% in 77% of those with
diabetes in whom HbA1c was measured at baseline (704/1,842; 38%).
Treatment intensification in the hypertension and diabetes cohorts across both the inter-
vention and control groups was common during the study period (Table 3), slightly favouring
the intervention group (44% versus 40% for hypertension and 57% versus 50% for diabetes),
although these differences were not significant when adjusted for stratification by sub-district
and clustering. For hypertension, the risk ratio (RR) was 1.08 (95% CI 0.94 to 1.24; p = 0.252);
for diabetes, the RR was 1.10 (95% CI 0.97 to 1.24; p = 0.126). Rates of treatment intensification
in the chronic respiratory disease cohort were low (14% in the intervention group versus 12%
in the control group) and not significantly different between groups (RR 1.08; 95% CI 0.75 to
1.55; p = 0.674). Fewer patients who screened positive for depression in the intervention group
reported receiving treatment for depression at follow-up than their control group counterparts
(18% versus 24%), but there was no difference between groups after adjustment for the trial’s
design (RR 0.76; 95% CI 0.53 to 1.10; p = 0.142). Adjustment for baseline characteristics
(Table 2) did not materially alter these results. The full regression models are presented in
Table D in S1 Appendix.
Pre-specified subgroup analyses by baseline level of disease control (Table 4) showed that,
in the diabetic cohort, the intervention was associated with treatment intensification only
among patients with baseline HbA1c of 7%–10% (RR 1.30; 95% CI 1.16 to 1.47; p-value for
interaction = 0.010). In the other cohorts, there were no significant differences in effectiveness
Table 2. (Continued)
Characteristic Intervention Control
HbA1c (percent): mean (range), median (IQR) 9 (4–17), 8 (7–10), n
= 310
9 (5–17), 9 (7–11), n
= 394
HbA1c 7% 227 (73), n = 310 317 (81), n = 394
Values are n (percent) unless stated otherwise.
1Housing density: number of occupants/number of rooms.
2Waist circumference >88 cm for women, >104 cm for men.
3Ten-year risk of cardiovascular disease death (sudden cardiac or stroke death). Score calculated for
patients with no known cardiovascular disease.
BMI, body mass index; BP, blood pressure; IQR, interquartile range; SD, standard deviation.
doi:10.1371/journal.pmed.1002178.t002
Evaluation of an Integrated Clinical Management Tool for Non-communicable Diseases
in Primary Care: A Cluster Randomised Trial
PLOS Medicine | DOI:10.1371/journal.pmed.1002178 November 22, 2016 15 / 27
between subgroups. However, treatment intensification tended to be more common, in both
arms, in subgroups with poorer control at baseline. The non-significant difference in depres-
sion treatment, which favoured the control group, was mostly among those already receiving
treatment for depression at baseline.
Disaggregated primary outcomes are presented in Table E in S1 Appendix. Notable findings
include apparently significantly higher rates of aspirin initiation among patients with hyper-
tension and diabetes attending intervention clinics, even though aspirin prescribing was
restricted to doctors. Angiotensin-converting enzyme (ACE) inhibitor use was significantly
higher among intervention group patients with known cardiovascular disease, as was sulpho-
nylurea use among intervention group diabetic patients with BMI 30 kg/m2. In the depres-
sion cohort, the higher rate of depression treatment in the control arm was because more
control group patients reported receiving counselling (15% in the intervention arm versus
22% in the control arm) and referral to psychiatric services (5% in the interventional arm ver-
sus 9% in the control arm). There was no significant difference between groups in the use of
antidepressants, which was very low (<5%).
Table 5 reports differences in cardiovascular risk factors between baseline and follow-up.
There were no differences between groups in terms of blood pressure, waist circumference,
BMI, or HbA1c. Smoking quit rates were high overall, but similar between groups. However,
readiness to quit smoking was significantly higher in the intervention group (odds ratio 1.73;
95% CI 1.17 to 2.57).
There were no differences between groups in health outcomes measured with the EuroQol-
5D [55], CESD-10 [32], or World Health Organization Disability Assessment Schedule 2.0
[56] (Table 6). Mortality did not differ between groups (Table 6). Healthcare utilisation, as
measured by clinic visits and hospital admissions during the 3 mo before the follow-up visit,
was similar between groups, but there was a statistically non-significant higher number of hos-
pital admissions in the intervention group (Table 7).
Table 3. Primary outcomes for each disease cohort.
Disease Cohort Outcome Intervention, n/N
(Percent)
Control, n/N
(Percent)
Effect Estimate: Risk Ratio ICC
Crude Model Adjusted Model
Estimate (95%
CI)
p-
Value
Estimate (95%
CI)
p-
Value
Hypertension Treatment
intensification
685/1,555 (44) 673/1,672 (40) 1.08 (0.94 to
1.24)
0.252 1.101 (0.96 to
1.27)
0.165 0.043
Diabetes Treatment
intensification
481/851 (57) 498/991 (50) 1.10 (0.97 to
1.24)
0.126 1.112 (0.99 to
1.26)
0.083 0.030
Chronic respiratory
disease
Treatment
intensification
81/586 (14) 68/571 (12) 1.08 (0.75 to
1.55)
0.674 1.223 (0.88 to
1.68)
0.228 0.011
Depression Case detection 224/1,253 (18) 283/1,186 (24) 0.76 (0.53 to
1.10)
0.142 0.804 (0.57 to
1.10)
0.167 0.077
1Adjusted for age, sex, body mass index, smoking status, diabetes, chronic respiratory disease, blood pressure control, maximal medical therapy at
baseline, history of cardiovascular disease.
2Adjusted for sex, body mass index, smoking status, hypertension, history of cardiovascular disease at baseline.
3Adjusted for age, smoking status, diabetes, history of tuberculosis, whether or not receiving respiratory medication at baseline.
4Adjusted for sex, smoking status, hypertension, history of depression, 10-item Center for Epidemiologic Studies Depression Scale score at baseline,
whether or not receiving antidepressant medication at baseline.
ICC, intraclass correlation coefficient.
doi:10.1371/journal.pmed.1002178.t003
Evaluation of an Integrated Clinical Management Tool for Non-communicable Diseases
in Primary Care: A Cluster Randomised Trial
PLOS Medicine | DOI:10.1371/journal.pmed.1002178 November 22, 2016 16 / 27
Discussion
This paper reports our evaluation of the clinical effectiveness of a complex health systems
intervention, based on task-shifting by adding nurse-led NCD and depression care to a proven
effective, and scalable, integrated care model for nurse-led care of communicable diseases, in
the context of limited availability of physicians to treat a high burden of multimorbid and
poorly controlled NCDs in a middle-income country.
The primary analyses found no statistically significant effects of the intervention on the pri-
mary outcomes for any of the four disease cohorts. These cohorts were analysed separately,
equivalent to four parallel trials; adjustment for having four primary outcomes instead of one
would only have decreased statistical differences. Health status outcomes also did not differ
between the intervention and control groups. But neither was there evidence of harm for any
of these endpoints, or in terms of reduced well-being or excess hospitalisations or deaths. In
Table 4. Subgroup analyses: primary outcomes stratified by level of disease control at baseline.
Baseline Subgroup (Pre-specified) Intervention, n/N
(Percent)
Control, n/N
(Percent)
Effect Estimate: Risk
Ratio
WALD p-
Value1
Estimate (95%
CI)
p-Value
Hypertension 0.444
BP uncontrolled2 546/1,127 (49) 545/1,268 (43) 1.12 (0.97 to
1.28)
0.113
BP controlled2 139/426 (33) 128/399 (32) 1.01 (0.76 to
1.33)
0.954
Diabetes 0.010
HbA1c < 7% 34/83 (41) 29/77 (38) 1.08 (0.77 to
1.52)
0.638
HbA1c 7%–10% 97/140 (69) 93/170 (55) 1.30 (1.16 to
1.47)
<0.001
HbA1c > 10% 62/87 (71) 107/147 (73) 0.97 (0.81 to
1.16)
0.703
Chronic respiratory disease: symptom score
subgroup
0.532
SGRQ symptom scoremedian 20/189 (11) 19/228 (8) 1.17 (0.66 to
2.07)
0.581
SGRQ symptom core >median 37/221 (17) 35/195 (18) 0.95 (0.65 to
1.39)
0.802
Chronic respiratory disease: activity score
subgroup
0.693
SGRQ activity scoremedian 36/256 (14) 34/273 (13) 1.07 (0.7 to 1.65) 0.744
SGRQ activity score >median 40/271 (15) 31/254 (12) 1.21 (0.77 to
1.92)
0.412
Depression 0.632
Receiving any treatment for depression3 76/278 (27) 127/336 (38) 0.74 (0.54 to
1.02)
0.063
Not receiving any treatment for depression3 148/990 (15) 156/860 (18) 0.84 (0.49 to
1.42)
0.510
1p-Values for arm-subgroup interaction.
2BP uncontrolled defined as130/80 mm Hg for patients with diabetes or a history of cardiovascular disease, and140/90 mm Hg for all other patients.
3Receiving treatment for depression defined as being on antidepressant medication at therapeutic dosage or having received counselling in the past year or
having been referred to psychiatric services in the last year.
BMI, body mass index; BP, blood pressure; SGRQ, St George’s Respiratory Questionnaire.
doi:10.1371/journal.pmed.1002178.t004
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addition, the intervention was not associated with higher healthcare utilisation at the primary
care or hospital level. A pre-planned subgroup analysis by baseline level of diabetes control
showed a benefit of the intervention in the subgroup of patients with moderately uncontrolled
diabetes (HbA1c 7%–10% at baseline), but the two other pre-specified subgroup analyses (for
hypertension and depression by baseline level of disease control) did not show a significant dif-
ference between groups.
While no primary outcomes showed a significant benefit of the intervention, the upper con-
fidence limits included the possibility of meaningful clinical improvements, and the direction
of results in three of the four primary endpoints in the study was consistent and positive. Also,
Table 5. Effect on cardiovascular disease risk and risk factors; all four cohorts pooled.
Risk/Risk Factor Measurement at Follow-Up Change between Baseline and Follow-Up
Intervention1 Control1 Intervention1 Control1 Effect Estimate p-
Value
ICC
Type Estimate (95%
CI)
CVD risk2 22.1 (20.0),
n = 1,550
24.9 (20.6),
n = 1,417
−0.4 (8),
n = 1,365
−1.1 (8),
n = 1,303
Diff in
means
0.54 (−0.51 to
1.59)
0.310 0.038
SBP (mm Hg) 134 (23.0),
n = 1,927
135 (21.7),
n = 2,049
1.2 (21.8),
n = 1,925
−1.1 (21.7),
n = 2,044
Diff in
means
2.00 (−0.87 to
4.87)
0.172 0.038
DBP (mm Hg) 88 (13.2),
n = 1,927
87 (12.7),
n = 2,049
0.0 (13.5),
n = 1,925
−1.8 (13.4),
n = 2,044
Diff in
means
1.58 (−0.56 to
3.72)
0.148 0.058
Proportion with
uncontrolled BP3
1,267/2,166 (58%) 1,325/2,227
(60%)
N/A N/A Risk ratio 1.024 (0.96 to
1.09)
0.464 0.024
Waist circumference (cm) 98.3 (16.7),
n = 1,886
99.6 (16.8),
n = 1,998
0.3 (8.4),
n = 1,867
0.8 (8.8),
n = 1,981
Diff in
means
−0.53 (−2.30 to
1.25)
0.563 0.131
Weight (kg) 77.2 (19.7),
n = 1,872
77.2 (19.2),
n = 1,992
−0.1 (6.5),
n = 1,866
−0.3 (6.5),
n = 1,985
Diff in
means
0.15 (−0.52 to
0.82)
0.665 0.024
BMI (kg/m2) 30.1 (7.6),
n = 1,866
30.5 (7.5),
n = 1,981
0.0 (2.5),
n = 1,863
−0.1 (2.6),
n = 1,979
Diff in
means
0.06 (−0.21 to
0.32)
0.672 0.024
HbA1c (percent) 9.1 (2.6), n = 285 9.5 (2.6),
n = 333
0.0 (2.4), n = 161 −0.2 (2.1),
n = 218
Diff in
means
0.21 (−0.43 to
0.85)
0.508 0.055
Proportion who smoke 480/2,166 (22%) 577/2,227 (26%) N/A N/A Risk ratio 0.885 (0.74 to
1.06)
0.178 0.037
Proportion who quit
smoking
167/574 (29%) 194/668 (29%) N/A N/A Risk ratio 1.01 (0.71 to
1.42)
0.971 0.049
Number of units smoked
per day
6.8 (6.1), n = 479 6.6 (5.1),
n = 578
−0.7 (5.7),
n = 406
−0.6 (5.7),
n = 578
Diff in
means
−0.08 (−1.07 to
0.91)
0.869 0.047
Readiness to quit smoking Odds ratio 1.73 (1.17 to
2.57)
0.006 0.104
• Thinking of quitting in
next 30 d
73/480 (15%) 66/577 (11%) N/A N/A
• Thinking of quitting in
next 6 mo
318/480 (66%) 337/577 (58%) N/A N/A
• Not thinking of quitting 89/480 (19%) 174/577 (30%) N/A N/A
1Mean (standard deviation) or n/N (percent).
2Ten-year risk of cardiovascular disease death (sudden cardiac or stroke death). Score calculated for patients with no known cardiovascular disease.
3Uncontrolled BP defined as130/80 mm Hg for patients with diabetes or a history of cardiovascular disease, and140/90 mm Hg for all other patients.
4Adjusted for uncontrolled BP at baseline, age, and sex.
5Adjusted for insulin at baseline, uncontrolled BP at baseline, BMI, sex, hypertension, and history of cardiovascular disease.
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; Diff, difference; DBP, diastolic blood pressure; ICC, intraclass correlation
coefficient; N/A, not applicable; SBP, systolic blood pressure.
doi:10.1371/journal.pmed.1002178.t005
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the pre-specified secondary analysis of patients with diabetes and uncontrolled HbA1c mea-
surements at baseline demonstrated a positive effect. After disaggregation of the disease
groups, other significant findings were higher rates of aspirin initiation among patients with
hypertension and diabetes, higher use of ACE inhibitors in patients with known cardiovascular
disease, and more prescriptions of sulphonylureas in patients with diabetes and a high BMI
(Table E in S1 Appendix).
The non-significant findings for the primary outcomes contrast with positive findings in
our three previous pragmatic randomised controlled trials using a similar integrated manage-
ment tool and the same training approach, focused on a narrower range of mainly communi-
cable conditions [9–15,30,42,59]. These trials showed modest, but consistent, improvements
across a range of process indicators and health and healthcare utilisation outcomes.
There are several potential reasons for the non-significant findings on the primary out-
comes of our study. One is the level of uptake of PC101 into daily clinical practice. Owing to
limited research funding, a complete and suitably detailed process evaluation of the uptake of
PC101 into clinical practice was not possible. However, limited focus group discussions and
Table 6. Effect on quality of life, depression, and mortality.
Outcome Measurement at Follow-Up Change between Baseline and Follow-Up
Intervention1 Control1 Intervention1 Control1 Effect Estimate p-
Value
ICC
Type Estimate (95%
CI)
EuroQol 5D index score2 0.8 (0.3),
n = 1,927
0.8 (0.2),
n = 2,050
0.0 (0.3),
n = 1,924
0.0 (0.3),
n = 2,045
Diff in
means
0.00 (−0.05 to
0.06)
0.855 0.078
EuroQol 5D visual analogue scale3 75.1 (20.3),
n = 1,927
74.0 (19.0),
n = 2,050
12.1 (29.8),
n = 1,924
6.4 (26.9),
n = 2,045
Diff in
means
6.06 (−3.25 to
15.36)
0.202 0.290
10-item Center for Epidemiologic
Studies Depression Scale4
8.0 (6.3),
n = 1,927
7.4 (6.1),
n = 2,050
−3.1 (6.8),
n = 1,926
−3.1 (7.3),
n = 2,050
Diff in
means
−0.12 (−1.72
to 1.48)
0.882 0.111
World Health Organization Disability
Assessment Schedule 2.05
17.1 (7.0),
n = 1,740
17.6 (6.3),
n = 1,933
N/A N/A Diff in
means
−0.09 (−1.27
to 1.09)
0.878 0.113
Mortality 64/2,166 (3%) 64/2,227 (3%) N/A N/A Risk ratio 1.11 (0.79 to
1.56)
0.564 0.003
1Mean (standard deviation) or n/N (percent).
2The EuroQol-5D index score is a weighted total between 0 and 1, where 0 = death and 1 = perfect health.
3The EuroQol-5D visual analogue scale is a score between 0 and 100 where 0 = worst imaginable state of health and 100 = best imaginable state of health.
4The 10-item Center for Epidemiologic Studies Depression Scale is scored from 0 to 30, with higher scores representing greater degrees of depressed
mood.
5The World Health Organization Disability Assessment Schedule 2.0 is scored from 12 to 60, with higher scores representing greater degrees of disability.
Diff, difference; ICC, intraclass correlation coefficient; N/A, not applicable.
doi:10.1371/journal.pmed.1002178.t006
Table 7. Effect on healthcare utilisation.
Outcome Intervention, Mean
(SD)
Control, Mean
(SD)
Effect Estimate ICC
Type Estimate (95%
CI)
p-Value
Number of hospital admissions in 3 mo before follow-up
interview
0.1 (0.4), n = 1,927 0.1 (0.3), n = 2,050 IRR 1.25 (0.91 to 1.71) 0.162 0.004
Number of inpatient days in 3 mo before follow-up interview 0.4 (2.8), n = 1,927 0.3 (2.4), n = 2,050 IRR 1.43 (0.83 to 2.48) 0.201 0.003
Number of clinic visits in 3 mo before follow-up interview 2.5 (1.7), n = 1,456 2.5 (1.4), n = 1,665 IRR 1.02 (0.93 to 1.13) 0.678 0.070
ICC, intraclass correlation coefficient; IRR, incidence rate ratio.
doi:10.1371/journal.pmed.1002178.t007
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observations in clinics by members of the research team confirmed heterogeneous uptake of
PC101 within and between clinics, as might be expected in a pragmatic trial intervention.
Overall low levels of uptake would seem unlikely, given the enthusiastic response and high
uptake of the method by clinic staff reported in our previous implementation studies with the
PALSA PLUS management tool [12,42]. Other factors should be considered, such as training.
The addition of NCD care to the training programme may have proved a step too far—the
content of the PC101 management tool was twice as substantial as that of the PALSA PLUS
tool—and potentially overwhelming for nurses who were still learning to implement nurse-ini-
tiated and -managed antiretroviral treatment when the trial started. Furthermore, NCDs have
long been managed by nurses in primary care clinics throughout South Africa, albeit with min-
imal training or intervention. As seen in the baseline characteristics, poor NCD care may have
become entrenched, and markers of poor disease control routinely ignored [60]. The challenge
of “undoing” these clinical habits and effecting a change in clinical behaviour is well described
and may take repeated training sessions to achieve. Although training was provided through-
out the trial, the comprehensive nature of PC101 made it difficult to cover the curriculum for
NCDs sufficiently within the time frame of the study. Owing to limited research funding, but
consistent with a pragmatic trial design, formal assessments of adequacy of training and uptake
(use) of PC101 were not performed.
A further potential reason for the failure to show differences between groups was the effect
of a co-intervention, the concurrent Chronic Disease Season campaign, instituted by the clinic
managers in both control and intervention clinics. The impact of this unforeseen development
is seen in the higher rates of treatment intensification for hypertension and diabetes (the focus
of the campaign) than for chronic respiratory disease or depressive symptoms in both the
intervention and control clinics. Whereas only 13% of patients with chronic respiratory disease
and 3% of those with depression had medication intensified at follow-up, nearly half of those
with hypertension and diabetes had intensified treatment (42% and 53%, respectively). These
rates of intensification of antihypertensive and diabetic medications are similar to or slightly
higher than those reported in high-income country settings [50,58].
Another consideration concerns methodology. We recruited all patients with the diseases
of interest rather than only those requiring treatment intensification, and failed to assess
adherence and exclude patients who did not adhere to previously prescribed medications and
who might therefore have been less likely to have been prescribed additional treatment. How-
ever, the eligibility criteria were adopted on the assumption that decision-makers wanted evi-
dence of effectiveness of the intervention across broad groups of patients, rather than for
subgroups, and that, as lack of disease control was highly prevalent at baseline, the majority of
patients would qualify for treatment intensification.
Other limitations of the study design include dependence on self-reported diagnoses for
inclusion in the patient cohorts, reliance on process outcomes, and insufficient resources to
measure important health outcomes, such as HbA1c, at follow-up. Also, the duration and tim-
ing of the follow-up data collection might not have been optimal for a study of chronic dis-
eases, where follow-up visits being only every 3–6 mo limited opportunities for treatment
intensification. This is illustrated by the low number of clinic visits during the follow-up
period, a mean of around 2.5 per patient over a period of 14 mo (Table 7).
The main strength of the study was that it was a pragmatic trial, implemented under routine
circumstances in a real-world setting with the intervention delivered by usual health depart-
ment trainers, with minimal research-related distortions of care delivery. Observing this real-
world implementation appears to have given relevant policy-makers sufficient confidence to
make a decision on the suitability of the intervention for their health systems. Other strengths
of the study include the cluster randomised design (appropriate to reduce the risk of
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contamination in an intervention directed at groups of nurses working in clinics), high follow-
up rates for both patient interviews and prescription data, the inclusion of four different
chronic diseases in a context characterised by high rates of multimorbidity, and identification
and follow-up of patient participants by fieldworkers independent of clinical care.
So what are the implications of the trial for decision-makers in South Africa and other
LMICs who are faced with overstretched health services and the need to address NCDs and
mental health? In October 2013, even before the trial results were finalised, decision-makers
were increasingly enthusiastic about the PC101 intervention, and both the Western Cape
Department of Health and the National Department of Health in South Africa elected to com-
mence implementation. Later dissemination of the trial findings on the effectiveness of this
intervention to these local and national policy-makers did not change this decision. The deci-
sion, we were told, was much more influenced by demand from frontline clinicians and man-
agers for what was perceived to be a highly feasible and acceptable approach to expanding
skills for NCDs. Further factors that may have influenced decision-makers were the benefits of
the new mode of clinician training reported in our prior studies [9,13,15], an independent
report supporting the integrated Chronic Care Model as a feasible component of health system
reform in South Africa [61], and the findings of a non-randomised evaluation of PC101 per-
formed in 42 primary care clinics in three additional health districts [62]. The PC101 manage-
ment tool is correctly seen as a means of overcoming the “silo” approach to individual disease
management in which recommendations for different conditions may vary and even conflict
and, more importantly, ensures that NCDs and mental health are not overlooked because of
prioritisation of communicable diseases. For us, as researchers who look to rigorous research
methods to guide health system development, this has been a powerful lesson in understanding
that evidence of effectiveness is only one element under consideration by decision-makers
[63]. Given clinicians’ strong attraction to the ease of integrating PC101 into clinic practice
and the positive system effects of our intervention mentioned above, it might have been more
useful to focus our primary analysis on lack of harm. For example, the study was not powered
to test for differences in healthcare utilisation and reasons for referrals and hospitalisations.
Thus, it is not possible to evaluate the significance of the small imbalance in numbers of hospi-
tal admissions between the intervention group and the control group, since an increase in hos-
pitalisations reflecting more appropriate referrals from primary care may be interpreted as
favourable rather than as a treatment failure. Specifically designed trials are required.
We now consider that it is our responsibility as health system researchers to invest in
improving the effectiveness of this intervention. There are patterns in the data from the trial
that provide reassurance that the intervention is not harmful and that, with further optimisa-
tion, might demonstrate improvements in effectiveness. Several adjustments have been made
to the programme that is being scaled up with the aim of increasing its impact on skills, clini-
cian confidence, and quality of care. The PC101 content has been broken down into four train-
ing modules (communicable diseases, NCDs, mental health, and women’s health) to allow
staff to become familiar with one area at a time and embed changes into their clinical practice
before moving to the next. We now also explicitly aim PC101 training at doctors, through ded-
icated workshops for professionals who would otherwise miss regular onsite training due to
the sessional nature of their work. Implementation workshops, with an extra day aimed at
meeting the needs of facility and middle managers, are included in the training of nurse train-
ers, and appointment of clinical governance teams within sub-districts allows local trouble-
shooting of barriers to implementation and inclusion of non-clinicians in the day-to-day
running of the programme. A further cluster randomised trial in the North West province of
South Africa (ClinicalTrials.gov NCT02407691) is currently evaluating the effect of the mental
health module when combined with the provision of manualised depression counselling by lay
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health workers delivered to ART patients with co-morbid depression. A second study is evalu-
ating this mental health module in patients with hypertension and co-morbid depression [64].
This expansion of human resources to include lay health workers is based on our experience
from the PC101 trial that nurse training alone is insufficient to close the gap in depression care
when there is limited access to treatment in the form of counselling services or antidepressant
prescriptions (prescribing currently restricted to doctors).
Although it will not be possible to conduct another randomised controlled trial of the
adapted PC101 implementation as it is scaled up, we plan to conduct such trials for future
national and international adaptations of this programme [17]. Ease of implementability
appears to be a major feature for policy-makers, and we will include proxies, such as accept-
ability to frontline clinicians, as outcome measures in future trials.
In conclusion, this pragmatic cluster randomised trial of the effects of an integrated man-
agement tool implemented using educational outreach to nurses showed no effect on treat-
ment intensification in patients with NCDs or on case detection of depression. But neither was
there evidence of harm. Despite this lack of positive clinical outcomes, decision-makers were
disposed to view PC101 as a coherent, feasible, and acceptable extension of a programme of
integrated care previously shown to be effective in the South African health system, and health
authorities have committed to a national rollout of an improved version of the PC101 pro-
gramme. The disjuncture between the clinical outcomes of our study and the policy choice
exposes the different responsibilities of researchers and decision-makers in a health system.
For us, as intervention developers, this focuses our attention on longer term improvements to
strengthen components of the programme in order to achieve clinical impact on care for
NCDs, while, as evaluators, we see the need for ongoing audit and further randomised prag-
matic controlled trials to evaluate the effectiveness of these improvements.
Health systems research and development is an interactive and deliberative process. Per-
haps the greatest contribution of this study lies in the relationships developed between our
team and health system decision-makers, during a series of five large randomised evaluations
of health systems interventions that responded to decision-maker-defined health systems
needs over 16 years [17]. To this process we have each brought our different skills and perspec-
tives, and together have developed, and are scaling up, an iteratively improved, evidence-
informed approach to nurse-led primary care that strengthens human resources and health
systems, and brings better care to South Africans, as well as models that can be applied in
other low- and middle-income country settings.
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